× Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our privacy policy



meta|Evidence breast cancer

Living evidence synthesis
about last generation of breast cancer treatment

Member of the meta|Evidence galaxy

Latest studies

ATEMPT, 2021

breast cancer - adjuvant

trastuzumab emtasine plus endocrine therapy

Bachelot, 2022

breast cancer - adjuvant

everolimus

DESTINY-Breast04, 2022

metastatic/advanced - breast cancer (mBC)

trastuzumab deruxtecan

NCT00454805, 2013

la/mBC - HR-positive - 1st line (L1)

cediranib plus fulvestrant

NEO-ORB (mutant cohort), 2019

la/mBC - HR positive - (neo)adjuvant (NA)

alpelisib plus letrozole

NCT02756364 (sapanisertib weekly), 2022

la/mBC - HR-positive - 2nd line (L2)

sapanisertib plus fulvestrant

NEO-ORB (buparlisib vs placebo), 2019

la/mBC - HR positive - (neo)adjuvant (NA)

buparlisib plus letrozole

SYSUCC-002, 2022

la/mBC - HER2 positive - 1st Line (L1)

trastuzumab plus endocrine therapy

KCSG-BR15-10, 2019

la/mBC - HR positive

palbociclib plus endocrine therapy

REACT, 2021

la/mBC - HR-positive - 2nd line (L2)

celecoxib plus endocrine therapy

Pimentel, 2019

la/mBC - HR-positive - 2nd line (L2)

metformin

Harbeck (TDM-1), 2017

es-BC - HER2 positive - (neo)adjuvant (NA)

trastuzumab emtansine

Harbeck (TDM1 plus ET), 2017

es-BC - HER2 positive - (neo)adjuvant (NA)

trastuzumab emtasine plus endocrine therapy

Huang, 2020

la/mBC - HR-positive - 2nd line (L2)

OBI-822/OBI-821 plus cyclophosphamide

QUILT-2.015, 2013

la/mBC - HR-positive - 2nd line (L2)

ganitumab plus endocrine therapy

NEO-ORB (wild type cohort), 2019

la/mBC - HR positive - (neo)adjuvant (NA)

alpelisib plus letrozole

MK-8669-064, 2017

la/mBC - HR-positive - 1st line (L1)

dalotuzumab plus ridaforolimus plus exemestane

ENCORE301, 2013

la/mBC - HR-positive - 2nd line (L2)

entinostat plus exemestane

BEECH, 2019

la/mBC - HR-positive - 1st line (L1)

capivasertib plus paclitaxel

NCT02187991 - HR-positive and HER2-negative cohort, 2021

la/mBC - HR-positive - 2nd line (L2)

alisertib plus paclitaxel

447
treatments 		  367
studies 		  1263
references
This project is supported by H2020 Qualitop, an EU-funded project, Hospices Civils de Lyon and CNRS UMR5558 LBBE.
     

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons